ArticlePharmaceutics2021
Effective Treatment against ESBL-Producing
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Prevalence and genotypic-phenotypic association of highly resistant Klebsiella pneumoniae in community-acquired urinary tract infections.BMC infectious diseases · 2025Article
- Beyond traditional therapies: a narrative overview of antimicrobial photodynamic therapy in combating bacterial and viral infections.Archives of microbiology · 2025Review
- Photodynamic Effectiveness of Copper-Iminopyridine Photosensitizers Coupled to Zinc Oxide Nanoparticles AgainstInternational journal of molecular sciences · 2025Article
- Exploring the potential of photodynamic therapy in overcoming multidrug resistance: mechanisms, synergies, and clinical advancements in infectious diseases.Frontiers in cellular and infection microbiology · 2025Review
- Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.Archives of microbiology · 2024Review
- Identifying the Molecular Fingerprint of Beta-Lactams via Raman/SERS Spectroscopy Using Unconventional Nanoparticles for Antimicrobial Stewardship.Antibiotics (Basel, Switzerland) · 2024Article
- Photoinactivation of microorganisms using bacteriochlorins as photosensitizers.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Editorial on the "Special Issue in Honor of Dr. Michael Weber's 70th Birthday: Photodynamic Therapy: Rising Star in Pharmaceutical Applications".Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundExtended-spectrum beta-lactamase (ESBL) and carbapenemase (KPC METHODOLOGY: Bimetallic Re(I)-based compounds, PSRe-µL1 and PSRe-µL2, were tested in aPDI and compared with a Ru(II)-based PS positive control. The ability of PSRe-µL1 and PSRe-µL2 to inhibit
resultsAt a minimum dose of 4 µg/mL, both the PSRe-µL1 and PSRe-µL2 significantly inhibited in 3log
conclusionCompounds PSRe-µL1 and PSRe-µL2 produce an effective and synergistic aPDI effect on KPC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.